|
Market Closed -
Nasdaq
05:00:00 20/11/2026 HKT
|
5-day change | 1st Jan Change | ||
| 199.33 USD | +1.29% |
|
-13.84% | +575.92% |
| 11-19 | Jefferies Adjusts Price Target on Moderna to $215 From $230 | MT |
| 11-18 | Moderna, Inc. Presents at Jefferies London Healthcare Conference, Nov-18-2026 11:00 AM |
| Market Cap | 80.65B 73.48B 68.02B 61.53B 115B 7,533B 121B 822B 326B 4,070B 303B 296B 12,894B | P/E 2026 * |
-27.3x | P/E 2027 * | -44.8x |
|---|---|---|---|---|---|
| Enterprise Value | 75.8B 69.06B 63.93B 57.82B 108B 7,079B 114B 773B 307B 3,825B 284B 278B 12,117B | EV / Sales 2026 * |
31.4x | EV / Sales 2027 * | 28.5x |
| Free-Float |
92.75% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| MRNA | Delayed | |
| MRNA | Real-time | ||
| 1MRNA | End-of-day quote | ||
| 0QF | Delayed | ||
| 0QF | Real-time | ||
| Real-time | |||
| 0QF | Real-time | ||
| 0QF | Delayed | ||
| 0QF | Delayed | ||
| 0A45 | Delayed | ||
| MRNA * | End-of-day quote | ||
| MRNA | End-of-day quote | ||
| MRNA_KZ | End-of-day quote | ||
| MRNAUS | End-of-day quote | ||
| 0A45 | Real-time | ||
| MRNA | Delayed | ||
| MRNA | Delayed |
Last Transcript: Moderna, Inc.
| 1 day | +1.29% | ||
| 1 week | -13.84% | ||
| Current month | -10.10% | ||
| 1 month | -12.15% | ||
| 3 months | +14.31% | ||
| 6 months | +335.98% | ||
| Current year | +575.92% |
| 1 week | 189.98 | 222.42 | |
| 1 month | 179.53 | 280.8 | |
| Current year | 29.81 | 280.8 | |
| 1 year | 22.28 | 280.8 | |
| 3 years | 22.28 | 280.8 | |
| 5 years | 22.28 | 376.65 | |
| 10 years | 11.54 | 497.49 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 54 | 01/03/2011 |
James Mock
DFI | Director of Finance/CFO | 49 | 06/09/2022 |
Stephen Hoge
PSD | President | 50 | 01/11/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Noubar Afeyan
CHM | Chairman | 63 | 01/02/2012 |
Stéphane Bancel
BRD | Director/Board Member | 54 | 01/03/2011 |
Francois Nader
BRD | Director/Board Member | 69 | 11/12/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 15/10/26 | Exercice | Chairperson | 192,049 | 0.0481% | ||
| 5/10/26 | Other | Chief Operating Officer | 125,000 | 0.0313% | ||
| 5/10/26 | Exercice | Chief Financial Officer | 3,612 | 0.0009% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.29% | -13.84% | +724.36% | +160.77% | 79.63B | ||
| -2.29% | -5.34% | +28.73% | +128.34% | 1,232B | ||
| -2.04% | -5.78% | +31.91% | +78.34% | 656B | ||
| -0.86% | -3.71% | +21.74% | +105.02% | 506B | ||
| -1.04% | -1.80% | +28.69% | +68.01% | 382B | ||
| -3.61% | -9.62% | +39.73% | +30.53% | 340B | ||
| -3.22% | -5.20% | +24.48% | +51.30% | 294B | ||
| -2.51% | -4.49% | -2.15% | +29.67% | 278B | ||
| -1.14% | -6.05% | +28.16% | +65.35% | 240B | ||
| -1.45% | -0.85% | +30.03% | +120.72% | 210B | ||
| Average | -1.69% | -4.16% | +95.57% | +83.80% | 422B | |
| Weighted average by Cap. | -1.98% | -3.02% | +40.10% | +89.18% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.41B 2.2B 2.04B 1.84B 3.46B 225B 3.62B 24.61B 9.76B 122B 9.06B 8.87B 386B | 2.69B 2.45B 2.27B 2.05B 3.85B 251B 4.03B 27.4B 10.87B 136B 10.08B 9.87B 430B |
| Net income | -2.9B -2.65B -2.45B -2.22B -4.16B -271B -4.35B -29.61B -11.75B -147B -10.9B -10.67B -464B | -1.68B -1.53B -1.42B -1.28B -2.4B -157B -2.51B -17.11B -6.79B -84.72B -6.3B -6.17B -268B |
| Net Debt | -4.86B -4.42B -4.1B -3.71B -6.95B -454B -7.27B -49.51B -19.64B -245B -18.22B -17.84B -776B | -3.93B -3.58B -3.31B -3B -5.62B -367B -5.89B -40.06B -15.89B -198B -14.74B -14.43B -628B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 19/11/26 | US$199.33 | +1.29% | 8,204,149 |
| 18/11/26 | US$196.79 | -4.84% | 6,986,325 |
| 17/11/26 | US$206.80 | -3.93% | 8,277,036 |
| 16/11/26 | US$215.27 | -3.63% | 7,023,751 |
| 13/11/26 | US$223.37 | -3.45% | 8,085,638 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- MRNA Stock
Select your edition
All financial news and data tailored to specific country editions


















